Citius Oncology, Inc.
NASDAQ:CTOR · NASDAQ Global Market
-$0.03 today
Vol 0.02M · Avg 0.14M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CTOR · Revenue to Net Income
Key Ratios
Analysis
$5.6M of revenue converted into -$42.5M of net income for the selected period. Gross margin is 40.1% and net margin is -434.1%, showing how much revenue survives after costs and taxes. EPS is $-0.47, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $344.8M | $725.6M | $804.0M |
| Gross Profit | $0 | $0 | $0 | $0 | $10.3B | $8.9B | $7.6B |
| Gross Margin | — | — | — | — | 45.5% | 9.8% | 28.9% |
| Research & Development | $6.4M +30.3% | $4.9M +16.1% | $4.2M -38.1% | $6.9M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $17.1M +9.3% | $15.6M +98.6% | $7.9M +175.8% | $2.9M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $23.5M +14.3% | $20.6M +69.7% | $12.1M +24.8% | $9.7M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $0 | $0 | $0 -100.0% | $9.7M | $1.2B | $374.2M | $1.2B |
| EBITDA | -$23.5M -14.2% | -$20.6M -69.7% | -$12.1M | $0 | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | — | — | — | — | 10.0% | 5.6% | 46.3% |
| Operating Income | -$23.5M -14.3% | -$20.6M -69.7% | -$12.1M -24.8% | -$9.7M | $10.6B | $12.3B | $14.0B |
| Operating Margin | — | — | — | — | 18.7% | 16.6% | 24.1% |
| Interest Income | $36.4K | $0 | $0 | $0 | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $218.0K | $0 | $0 | $0 | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$181.7K | $0 | $0 | $0 | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$23.7M -15.2% | -$20.6M -69.7% | -$12.1M -24.8% | -$9.7M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | — | — | — | — | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $1.1M +83.5% | $576.0K +0.0% | $576.0K -50.0% | $1.2M | $666.8M | $1.3B | -$1.6B |
| Net Income | -$24.8M -17.1% | -$21.1M -66.6% | -$12.7M -16.9% | -$10.9M | $5.0B | $4.9B | $4.8B |
| Net Margin | — | — | — | — | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$0 -13.3% | -$0 -57.9% | -$0 -149.0% | -$0 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$0 -13.3% | -$0 -57.9% | -$0 -149.0% | -$0 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $73.3M +2.4% | $71.6M -20.0% | $89.5M -0.8% | $90.2M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $73.3M +2.4% | $71.6M -20.0% | $89.5M -0.8% | $90.2M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Forte Biosciences, Inc.
NASDAQ:FBRX
$243.83M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Owlet, Inc.
NYSE:OWLT
$84.14M
Scilex Holding Company
NASDAQ:SCLX
$72.18M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Actuate Therapeutics Inc
ACTU
$48.33M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CTOR generate?
Citius Oncology, Inc. (CTOR) reported $0.00 of revenue in fiscal 2025.
Is CTOR profitable?
Citius Oncology, Inc. (CTOR) reported -$24,761,369.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.